B-acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia [Phase 3]
Phase 3 trial evaluating inotuzumab ozogamicin with frontline chemotherapy for newly diagnosed B-ALL in young adults is currently recruiting…
-
CLINICAL_TRIALS trial_result · 2024-04-22Clinical Trial Update: CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). [Phase 2]
Phase 2 trial evaluating CD19CD22 CAR-T therapy in high-risk B-ALL, including Ph-negative ALL patients.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations [Phase 3]
Phase 3 trial evaluating combination chemotherapy in young patients with newly diagnosed high-risk B-ALL and Ph-like mutations; study is com…
-
CLINICAL_TRIALS trial_result · 2022-10-03Clinical Trial Update: Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia [Phase 4]
A Phase 4 clinical trial investigating immune factors associated with relapse in childhood B-lineage acute lymphoblastic leukemia has been t…
-
CLINICAL_TRIALS trial_result · 2021-02-01Clinical Trial Update: CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) [Phase 1, Phase 2]
Phase 1/2 trial updates for AUTO3 (CD19/22 CAR T cells) in B-cell acute lymphoblastic leukemia, including recurrent/refractory pediatric cas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-10-07Clinical Trial Update: Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL) [Phase 2]
Phase 2 trial of trastuzumab for HER2-positive relapsed/refractory B-acute lymphoblastic leukemia has been terminated.